Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

331 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
Cortellini A, Ricciuti B, Facchinetti F, Alessi JVM, Venkatraman D, Dall'Olio FG, Cravero P, Vaz VR, Ottaviani D, Majem M, Piedra A, Sullivan I, Lee KA, Lamberti G, Hussain N, Clark J, Bolina A, Barba A, Benitez JC, Gorría T, Mezquita L, Hoton D, Aboubakar Nana F, Besse B, Awad MM, Pinato DJ. Cortellini A, et al. Among authors: lamberti g. Ann Oncol. 2021 Nov;32(11):1391-1399. doi: 10.1016/j.annonc.2021.08.1744. Epub 2021 Aug 13. Ann Oncol. 2021. PMID: 34400292 Free article.
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, Cortinovis DL, Lamberti G, Facchinetti F, Pilotto S, Verusio C, Chella A, Bonanno L, Galetta D, Cappuzzo F. Chiari R, et al. Among authors: lamberti g. Clin Lung Cancer. 2020 Jan;21(1):15-20. doi: 10.1016/j.cllc.2019.06.012. Epub 2019 Jun 18. Clin Lung Cancer. 2020. PMID: 31607443 Clinical Trial.
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.
Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Abu-Sbeih H, et al. Among authors: lamberti g. J Clin Oncol. 2020 Feb 20;38(6):576-583. doi: 10.1200/JCO.19.01674. Epub 2019 Dec 4. J Clin Oncol. 2020. PMID: 31800340 Free PMC article.
Antibody-drug conjugates for lung cancer in the era of personalized oncology.
Ricciuti B, Lamberti G, Andrini E, Genova C, De Giglio A, Bianconi V, Sahebkar A, Chiari R, Pirro M. Ricciuti B, et al. Among authors: lamberti g. Semin Cancer Biol. 2021 Feb;69:268-278. doi: 10.1016/j.semcancer.2019.12.024. Epub 2019 Dec 30. Semin Cancer Biol. 2021. PMID: 31899248 Review.
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, Lo YC, Li YY, Lamberti G, Nguyen T, Milan MSD, Venkatraman D, Umeton R, Paweletz CP, Albayrak A, Cherniack AD, Price KS, Fairclough SR, Nishino M, Sholl LM, Oxnard GR, Jänne PA, Awad MM. Recondo G, et al. Among authors: lamberti g. Clin Cancer Res. 2020 Jun 1;26(11):2615-2625. doi: 10.1158/1078-0432.CCR-19-3608. Epub 2020 Feb 7. Clin Cancer Res. 2020. PMID: 32034073
331 results